168 related articles for article (PubMed ID: 17515695)
1. Mandatory comparator trials for therapeutically similar drugs: an assessment of the facts.
Milne CP; Kaitin KI; Dimasi JA
Am J Ther; 2007; 14(3):231-4. PubMed ID: 17515695
[No Abstract] [Full Text] [Related]
2. US court rules to allow experimental drugs for dying patients.
Waltz E
Nat Med; 2006 Jun; 12(6):596. PubMed ID: 16760988
[No Abstract] [Full Text] [Related]
3. [The 12th German Drug Law (AMG) amendment: an obstruction for non-commercial clinical trials?].
Schwarz S; Frölich L; Striebel JP; Hennerici MG
Dtsch Med Wochenschr; 2007 Jan; 132(3):108-12. PubMed ID: 17219346
[No Abstract] [Full Text] [Related]
4. EMEA tackles "generic" biologic drug issues.
Rice M
J Natl Cancer Inst; 2006 Apr; 98(7):435-6. PubMed ID: 16595776
[No Abstract] [Full Text] [Related]
5. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
Ochs A
Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540
[No Abstract] [Full Text] [Related]
6. Drive for drugs leads to baby clinical trials.
Nature; 2006 Mar; 440(7083):406-7. PubMed ID: 16554774
[No Abstract] [Full Text] [Related]
7. Second thoughts: do the FDA's responses to a fatal drug trial and the AIDS activist community's doubts about early access to drugs hint at a shift in basic FDA policy?
Lovell MC
Food Drug Law J; 1996; 51(2):273-94. PubMed ID: 11820202
[No Abstract] [Full Text] [Related]
8. How similar do 'biosimilars' need to be?
Schellekens H
Nat Biotechnol; 2004 Nov; 22(11):1357-9. PubMed ID: 15529154
[No Abstract] [Full Text] [Related]
9. Pediatric drug development in anesthesiology: an FDA perspective.
Schultheis LW; Mathis LL; Roca RA; Simone AF; Hertz SH; Rappaport BA
Anesth Analg; 2006 Jul; 103(1):49-51. PubMed ID: 16790624
[No Abstract] [Full Text] [Related]
10. Charging for investigational drugs under an investigational new drug application. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
[TBL] [Abstract][Full Text] [Related]
11. EU directive on clinical trials penalizes small sponsors.
Meldolesi A
Nat Biotechnol; 2003 Aug; 21(8):838. PubMed ID: 12894186
[No Abstract] [Full Text] [Related]
12. In U.S., biosimilars still await FDA decision.
Finkelstein JB
J Natl Cancer Inst; 2006 Apr; 98(7):435. PubMed ID: 16595775
[No Abstract] [Full Text] [Related]
13. Pediatric study of medicines becomes mandatory.
Bonetta L
Nat Med; 2000 Oct; 6(10):1069. PubMed ID: 11017118
[No Abstract] [Full Text] [Related]
14. Marketing drugs too early in testing.
Begg CB; Brawley O; Califf RM; Demets DL; Ellenberg SS; Kaplan RS
Science; 2006 Apr; 312(5771):195. PubMed ID: 16614197
[No Abstract] [Full Text] [Related]
15. Bioavailability and bioequivalence trials: statistics & pharmacokinetic principles.
Rajaram L; Roy SK; Skerjanec A
Stud Health Technol Inform; 2004; 103():159-79. PubMed ID: 15747918
[TBL] [Abstract][Full Text] [Related]
16. No way to save a life: allowing terminally ill patients access to drugs that have not completed clinical trials is a dangerous move.
Moss RW
New Sci; 2006 Jun 3-9; 190(2554):21. PubMed ID: 16832956
[No Abstract] [Full Text] [Related]
17. Dying to live.
Nat Med; 2006 Jun; 12(6):593. PubMed ID: 16760985
[No Abstract] [Full Text] [Related]
18. Regulation with placebo effects.
Malani A
Duke Law J; 2008 Dec; 58(3):411-72.. PubMed ID: 19353835
[TBL] [Abstract][Full Text] [Related]
19. EU law mandates drug testing in children.
Sinha G
J Natl Cancer Inst; 2008 Jan; 100(2):84-5. PubMed ID: 18182609
[No Abstract] [Full Text] [Related]
20. The end of the beginning?
Nat Biotechnol; 2006 Apr; 24(4):367. PubMed ID: 16601702
[No Abstract] [Full Text] [Related]
[Next] [New Search]
